<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), achievement of complete remission with first-line chemotherapy remains a challenging issue, as most patients who respond remain disease-free, whereas those refractory have few options of being rescued with salvage therapies </plain></SENT>
<SENT sid="1" pm="."><plain>The mechanisms underlying <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> chemoresistance and how it can be circumvented remain undetermined </plain></SENT>
<SENT sid="2" pm="."><plain>We previously reported the frequent inactivation of the proapoptotic BIM gene in B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Here we show that BIM epigenetic silencing by concurrent promoter hypermethylation and deacetylation occurs frequently in primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> samples and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-derived cell lines </plain></SENT>
<SENT sid="4" pm="."><plain>Remarkably, patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> with hypermethylated BIM presented lower complete remission rate (24% vs 79%; P = .002) and shorter overall survival (P = .007) than those with BIM-expressing <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, indicating that BIM transcriptional repression may mediate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> chemoresistance </plain></SENT>
<SENT sid="5" pm="."><plain>Accordingly, by combining in vitro and in vivo studies of human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-xenografts grown in immunodeficient RAG2(-/-)γc(-/-) mice and of murine B220(+)IgM(+) B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> generated in Eμ-MYC and Eμ-MYC-BIM(+/-) transgenes, we demonstrate that <z:hpo ids='HP_0002665'>lymphoma</z:hpo> chemoresistance is dictated by BIM gene dosage and is reversible on BIM reactivation by genetic manipulation or after treatment with <z:chebi fb="0" ids="15358">histone</z:chebi>-deacetylase inhibitors </plain></SENT>
<SENT sid="6" pm="."><plain>We suggest that the combination of <z:chebi fb="0" ids="15358">histone</z:chebi>-deacetylase inhibitors and high-dose chemotherapy may overcome chemoresistance, achieve durable remission, and improve survival of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
</text></document>